

Press Release

New benchmarks in predictability

One-month study on LASIK with SCHWIND AMARIS® 750S available

Kleinostheim, Germany, September 2010

Extremely high predictability of planned results is substantiated by the one-month results of a LASIK study where the new SCHWIND AMARIS 750S laser system with a pulse frequency of 750 Hertz was used for the first time. The study with 225 eyes was carried out by Dr. Maria Clara Arbelaez, Oman. Treated were myopic patients, either pure or with astigmatism, between 17 and 42 years of age. The preoperative spherical equivalent (SEQ) ranged from -0.50 D to -9.50 D, astigmatism was treated up to -4.75 D. The „Aberration-Free“ treatment was employed in all cases with the SCHWIND CAM software. 95% of all treatments (213/225 eyes) were carried out with static cyclotorsion control (SCC).

A postoperative SEQ averaging -0.14 with a standard deviation of 0.18 D was observed. The scattering of the results was very small: Already after one month, 85% of treated eyes achieved the planned refractive outcome with a minimal deviation of a quarter dioptre. 100% of treated eyes were within a range of only half a dioptre (fig. 1), 43% showed absolute emmetropia with ± 0 D. The clinical data are also impressive regarding safety: Already one month after treatment, 19% of treated eyes gained one Snellen line (fig. 2). High postoperative stability was observed already after one week. The fast approach towards the planned refractive result implies that the recovery time after treatment with the 750S, even with the extremely high pulse frequency of 750 Hz, is very short.

The excellent early results are also promising insofar as in view of the previous three and six month studies with the SCHWIND AMARIS a further improvement can be expected.

Contact:

SCHWIND eye-tech-solutions GmbH & Co. KG

Antje Splittdorf

fon: +49 (0) 60 27 / 5 08-164 · fax: +49 (0) 60 27 / 5 08-246

email: antje.splittdorf@eye-tech.net




Fig. 1: Refractive outcome – percentage within attempted




Fig. 2: Change in BSCVA - Safety